ANDA 210032, held by Sciegen Pharms. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 210032 (Azelastine Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Aug 23, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.2055MG/SPRAY ยท spray, metered;nasal | Azelastine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters